Navigation Links
Kalorama: Acquisitions Trending in Dermatological Drugs Market
Date:11/17/2015

NEW YORK, Nov. 17, 2015 /PRNewswire/ -- LEO Pharma's acquisition of the global dermatology business of Astellas Pharma for almost $725 million confirms Kalorama Information's projection that the worldwide pharmaceutical sector will only expand through mergers and acquisitions for some time to come. The healthcare market researcher's report, World Market for Prescription Dermatological Drugs, represents the ninth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors that may help to shape the market for treatments in the future.

World Market for Prescription Dermatological Drugs, 9th Edition, can be found at Kalorama Information: http://www.kaloramainformation.com/Prescription-Dermatological-Drugs-9251725/.  

Kalorama Information Logo
Kalorama Information Logo

"The worldwide pharmaceutical sector represents a significant opportunity," said Bruce Carlson, Publisher of Kalorama Information. "The financial struggles of 2009-2014 have created an impressive buyer's market for larger companies, as smaller firms struggle to extend financing."

The pharmaceutical industry is facing a tougher environment in general, due to harder regulations for gaining approvals for mainstream products, economic issues, and a dwindling pipeline of new products. Reliance on blockbuster drugs is all but over, causing a shift of focus for many drug research and development entities. By focusing on cosmetic medications, many manufacturers are realizing less scrutiny from the FDA and a growing need in the niche markets such as dermatology. This transition will play a role in the future development of the dermatological industry in the years ahead. The pharmaceutical sector has little choice but to continue expanding through mergers and acquisitions for some time to come. True globalization of pharmaceuticals has arrived. Most of the growth in the next few years will be outside the US, Europe and Japan. It's a very dynamic time for the industry focusing on a worldwide market.

LEO Pharma, an independent, research-based pharmaceutical company that develops, manufactures, and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally, is acquiring the assets related to Tokyo-based Astellas' treatments of acne and skin infections, including Protopic® for atopic dermatitis (except in Japan).

The driving forces for the prescription dermatological drugs market include growth and aging of the worldwide population, new products and technologies, and focus on lifestyle treatments that improve the effects of aging and damage to the skin. Within the pharmaceutical industry as a whole, financial depression, consolidation and economic downturns have influenced the market.

The worldwide market for prescription dermatology drugs includes products in the following categories:

  • Prescription Acne and Rosacea Drugs
  • Prescription Antiaging and Photodamage Drugs
  • Prescription Dermatitis and Seborrhea Drugs
  • Prescription Fungal Infection Drugs
  • Prescription Hair Loss and Hair Removal Drugs
  • Prescription Hyperpigmentation/Melasma Drugs
  • Prescription Psoriasis Drugs
  • Prescription Skin Cancer Drugs
  • Other Prescription Skin Disorder Drugs

World Market for Prescription Dermatological Drugs, 9th Edition, details the various categories of prescription dermatological drugs, describes the worldwide market for prescription dermatological drugs, and identifies major market factors that may help to shape the worldwide market for prescription dermatological drugs in the future.

All market data in the report pertains to the worldwide market at the manufacturers' level. Data are expressed in current U.S. dollars. The base year for data was 2015. Historical data are provided for each of the years 2013 to 2014, and forecast data are provided for each of the years 2015 through 2020. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2015 base year. Leading companies in the industry are profiled as well.

World Market for Prescription Dermatological Drugs, 9th Edition, can be found at Kalorama Information: http://www.kaloramainformation.com/Prescription-Dermatological-Drugs-9251725/.  

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.  

Contact:
Bruce Carlson
(212) 807-2622
bcarlson@kaloramainformation.com

Logo - http://photos.prnewswire.com/prnh/20140801/132634

 

 


'/>"/>
SOURCE Kalorama Information
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Kalorama: Billion-dollar Plus Market for Flow Cytometry Used in Clinical Testing
2. Kalorama: Antibiotic Drug Resistance Leads to HAI Deaths
3. Kalorama: Tax Savings Not Only Benefit to Medtronic-Covidien Deal
4. Kalorama: EMR Paves the Way for Big Data
5. Kalorama: Biopharmaceutical Manufacturing Services Market Reaches 36.8 Billion
6. Kalorama: 2014 The "Year of The Buy" in Medical Device Industry
7. Kalorama: Steady Growth in the Medical MRI Market
8. Kalorama: X-Ray and Digital X-Ray Market Nears 8 Billion This Year
9. Kalorama: Robot-Assisted PCR Among Innovations Driving Market
10. Kalorama: 3T Advancements Bringing New Growth to the MRI Market
11. Kalorama: XR-29 and Innovations Spur Global CT Scanner Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2020)... ... February 19, 2020 , ... A new study released ... oxygen-deprived clusters throughout the damaged site of a compressed spinal cord. It is also ... viral vector to target the oxygen-deprived sites enhances the injured spinal cord’s recovery. ...
(Date:2/19/2020)... ... February 19, 2020 , ... The Team Type 1 Foundation, a ... for everyone affected by diabetes, announced a partnership with VeloCity, a fundraising ride benefiting ... annual VeloCity event takes place on May 2nd and begins on the Mercedes-Benz Stadium ...
(Date:2/16/2020)... ... 2020 , ... In Partnership with the Smiles for Everyone Foundation , ... office. , A limited number of appointments are available, but there is plenty of ... to schedule an appointment, please call (509)-820-4302. , Who: Bright Now! Dental, Where: ...
Breaking Medicine Technology:
(Date:2/14/2020)... ... 2020 , ... Cloudticity announced today it has released a ... healthcare organizations using Amazon Web Services (AWS). , “Our customers want to leverage ... so,” explained Cloudticity Founder & CEO, Gerry Miller. “In service to our customers, ...
(Date:2/13/2020)... ... 2020 , ... The Root Cause Coalition, representing 77 organizations ... all Americans will unveil its new Status of Health Equity Report and discuss ... Club. , The event will feature a presentation and discussion of the Coalition’s ...
(Date:2/13/2020)... ... February 13, 2020 , ... The largest fertility center ... Fair Oaks, Fairfax, Fredericksburg, Leesburg, and Woodbridge, as well as two locations in ... have been named as Top Docs for Infertility by Northern Virginia Magazine. ...
(Date:2/13/2020)... ... February 13, 2020 , ... A January 24 article from Refinery29 ... in 2020. It also reports on a well-documented dramatic and ongoing increase over the ... his patients are increasingly knowledgeable and are asking about a number of both traditional ...
(Date:2/11/2020)... ... February 11, 2020 , ... ... and solutions, today announced its move to a new, significantly larger business premises ... base alongside significant expansion in the development of digital technology platforms. , “As ...
Breaking Medicine News(10 mins):